Drug discovery

The Francis Crick Institute
#DDW Turning Science into Business Symposium #Drug discovery #Events #The Francis Crick Institute

Dr Daniil Bash, Cambridge University, confirmed for DDW Symposium

The DDW Turning Science into Business Symposium will take place at the Francis Crick Institute in London on Tuesday 4 November. Daniil Bash DDW is delighted to welcome Dr Daniil Bash, Lead Scientist at the Innovation Centre in Digital Molecular Technologies (iDMT), University of Cambridge,… Read More

#News

Human brain
#Biomarkers #Drug discovery #Neurology #Neuroscience #Whitepaper

Navigating neurological biomarker research: Download the Whitepaper

Neurological biomarker research is advancing rapidly, but key challenges remain. Download this new Whitepaper from Olink entitled ‘Navigating neurological biomarker research: Progress, learnings and future directions’. The Whitepaper captures: Expert perspectives from academia and biopharma Highlighting successes, setbacks, and strategies for translational advancements in Alzheimer’s, Parkinson’s, and MS. A… Read More

#News

#Biomarkers #Drug discovery #Neurology #Neuroscience #Whitepaper

Navigating neurological biomarker research: Progress, learnings and future directions

Neurological biomarker research is advancing rapidly, but key challenges remain. This Whitepaper captures: Expert perspectives from academia and biopharma Highlighting successes, setbacks, and strategies for translational advancements in Alzheimer’s, Parkinson’s, and MS. A must-read for researchers navigating the future of precision neurology. Read More

#Resources #Whitepapers

Molecules
#Drug design #Drug development #Drug discovery #Structural biology #Webinar

Tomorrow: Drive breakthroughs with structure-guided drug design

Join DDW and Curia on 14 October for a webinar on how X-ray crystallography can accelerate the drug design process. The first challenge in drug discovery is selecting a biological target and validating it as a ‘druggable’ binding site. The key to this is identifying several… Read More

#News

#Artificial intelligence (AI) #Drug discovery

Accelerating drug discovery with technology 

David Nirschl, Head, Life Sciences Consulting, Thermo Fisher Scientific and Santosh Vijay, Senior Director, Program Management, Thermo Fisher Scientific explore how to harness innovation for speed, scale and personalisation in the lab.  The drug discovery journey has always been complex, and as scientists have moved from one hypothesis to the… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Biomarkers #Drug discovery #Personalised medicine #Webinar

Webinar: Explore AI strategies to streamline biomarker discovery

Biomarker discovery and validation are critical for advancing personalised medicine and improving therapeutic outcomes. However, the complexity of high-throughput assays and image-based analyses presents significant challenges in extracting meaningful insights efficiently. Taking place on 23 October at 4pm BST, this webinar, hosted by DDW and supported by Danaher Life… Read More

Webinar date:
Supported by Danaher
#News

Genomics
#Data #Drug discovery #Genomics #Multi-omics

Advancing drug discovery through multiomics  

John Lepore, MD, CEO of ProFound Therapeutics, explore how multiomics, combined with artificial intelligence and real-world data is advancing drug discovery. The drug discovery landscape is undergoing a transformative shift, driven by the growing demand for precision medicine and tremendous technological advances that inform systems biology. Traditional R&D approaches that… Read More

#Exclusive Content

Female researcher in a laboratory
#CRO #Drug development #Drug discovery #Translational chemistry

Integrating translational and clinical research to advance drug development

Dr Kenneth Barr, Head of Strategic Collaborations at Syngene, explores how early-phase drug development is moving towards integrated translational strategies.   Drug development continues to grow in complexity, risk, and cost. With timelines stretching over a decade and the average spend per new drug exceeding $2.6 billion, many pharmaceutical and… Read More

#Exclusive Content

UK and US flags
#Artificial intelligence (AI) #Biotechnology #Drug discovery #UK #United States

What does the US-UK tech partnership mean for AI drug discovery?

The recent state visit to the UK by US President Trump was accompanied by the unveiling of a ‘US-UK tech partnership’ on 16 September. DDW speaks to experts at MHA’s life science team, who advise biotechnology and pharma firms in both the UK and US, on what this means for… Read More

#Exclusive Content

#DDW Highlights podcast #Drug discovery #Podcast

Podcast: Catch up on the latest drug discovery news

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the week to keep DDW subscribers up-to-date with the latest industry news. This week’s news is led by the agreement by Genmab to acquire Merus, an announcement… Read More

#News

The Francis Crick Institute
#DDW Turning Science into Business Symposium #Drug discovery #Events #The Francis Crick Institute

Lawrence Welch, Nuclera, confirmed to speak at DDW Symposium

The DDW Turning Science into Business Symposium will take place at the Francis Crick Institute in London on Tuesday 4 November. Lawrence Welch DDW is delighted to welcome Lawrence Welch, Inside Sales Specialist, Nuclera, to the expert speaker line-up. Lawrence Welch supports the… Read More

#News

#Drug discovery

Case Study – A Free Energy Perturbation (FEP) study: Identifying ‘new’, active ligands for TYK2

In this case study, we test the predictive abilities of Free Energy Perturbation (FEP) to arrive at accurate binding free energies for ‘new’ ligand suggestions within the TYK2 system.   Computational methods used include: Molecular Dynamics (MD) Water analysis solving the Ornstein-Zernike equation (3D-RISM) Alignment of ligands for FEP (Conformation… Read More

#Case Studies

Antibody-drug conjugate
#Antibody drug conjugate (ADC) #Drug discovery #eBook #Therapeutic Antibodies

eBook: The impact of ADCs on drug discovery

Antibody-drug conjugates (ADCs) offer a targeted approach to cancer treatment, combining the specificity of antibodies with the potency of cytotoxic drugs, and have shown promise in improving patient outcomes. They have enjoyed considerable commercial success, particularly in treating cancer, and as a result various different types… Read More

#News

#Alys Pharmaceuticals #Atopic dermatitis #Biotechnology #Cold Urticaria #Dermatology #Drug discovery #Mastocytosis #Seed funding #Systemic mastocytosis

New podcast: First-in-class mechanisms for the next wave of dermatology innovation

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Thibaud Portal, Founder… Read More

#News

Vaccine
#Clinical trials #Drug development #Drug discovery #Vaccines

Developing a new targeted vaccine for Pneumococcal disease in Malawi 

Earlier this year, the Infection Innovation Consortium: iiCON and partners launched the first human challenge trial for a new vaccine for pneumococcal disease – marking a key milestone in a collaborative global project that is offering new hope in the fight against the disease. Professor Stephen Gordon, Director of Experimental… Read More

#Exclusive Content